Angarus Therapeutics, Inc.

PORTOLA VALLEY, CA · Founded 2018 · CIK 0001836891 · Biotech · Private

Biotechnology therapeutics (company defunct)

angarustx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$6.9M
1 Form D · Dec 2020
69 months since last filing
Contracts
—
No federal contracts on record
Patents
9
0 granted · 9 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$6,883,438
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
18643D Bio Holdings, Inc.—$7.8M
1865Tetragenetics, Inc.—$7.1M
1866Regenerative Medical Solutions Inc—$7.0M
1867Angarus Therapeutics, Inc.—$6.9M
1868Evoke Pharma Inc—$6.0M
1869Kiniksa Pharmaceuticals—$5.9M
1870Jennerex, Inc.—$5.4M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Peter LangeckerDirector
  • Chih-Ping LiuDirector
  • Jean LiuDirector
  • Nigel RayDirector · Executive Officer

Patents

USPTO · 0 granted of 9
  • ENPP1 Inhibitors As Inhibitors Of Metastasisapplication
  • ENPP1 Inhibitors And Immune Cells Expressing Chimeric Antigen Receptorsapplication
  • ENPP1 Inhibitors And Methods Of Modulating Immune Responseapplication
  • ENPP1 Inhibitors As Inhibitors Of Metastasisapplication
  • ENPP1 Inhibitors And Immune Cells Expressing Chimeric Antigen Receptorsapplication
  • ENPP1 Inhibitors As Inhibitors Of Metastasisapplication
  • ENPP1 Inhibitors And Immune Cells Expressing Chimeric Antigen Receptorsapplication
  • ENPP1 Inhibitors And Methods Of Modulating Immune Responseapplication
  • ENPP1 Inhibitors And Methods Of Modulating Immune Responseapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.